EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repositioning Triazoles as Phosphodiesterase‐4 Inhibitors to Suppress COVID ‐19 Cytokine Storms and Fungal Co‐Infections via Docking and Simulation

Hailah M Almohaimeed, Aniruddha Chatterjee, Majedah Ramadan Alaqabawi, Fayez Alsulaimani, Ahmed M Basri, Ayman Jafer, Abdullah F Shater, Fayez M Saleh, Bikram Dhara iD, Daniel Ejim Uti iD, Esther Ugo Alum

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Hailah M Almohaimeed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Triazoles, Phosphodiesterase 4 Inhibitors, COVID-19 Drug Treatment, Drug Repositioning. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe COVID‐19 cases are often characterised by a hyperinflammatory cytokine storm, which leads to immune dysregulation and increased mortality. Simultaneously, opportunistic fungal infections such as mucormycosis have been increasingly reported, especially in immunocompromised individuals. Triazole antifungals are widely used to treat such infections, but their potential immunomodulatory effects remain underexplored. This study aimed to investigate the off‐target potential of commonly used antifungal triazoles itraconazole, ketoconazole, posaconazole and voriconazole against human phosphodiesterase‐4 (PDE‐4), a key enzyme involved in the regulation of pro‐inflammatory cytokine expression. To our knowledge, this is the first study to explicitly propose and computationally validate the dual role of triazole antifungals as both antifungal and immunomodulatory agents. A computational approach comprising molecular docking, molecular dynamics (MD) simulations and quantum chemical analysis was employed to evaluate the interaction of the selected triazoles with PDE‐4. Binding affinity and interaction stability were compared with roflumilast, a known PDE‐4 inhibitor. Among the tested triazoles, posaconazole exhibited the most favourable binding energy (−44.60 kcal/mol via MM‐GBSA), forming stable interactions with key residues in the catalytic site of PDE‐4, similar to those observed with roflumilast. MD simulations further confirmed the binding stability of posaconazole, as evidenced by favourable RMSD and hydrogen bonding patterns. Quantum chemical analysis indicated strong electrophilicity and reactivity of posaconazole, supporting its potential PDE‐4 inhibitory activity. The findings suggest that certain triazole antifungals, especially posaconazole, may both fight fungal infections and reduce the cytokine storm in severe COVID‐19, offering a promising rapid‐response therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesPhosphodiesterase 4 InhibitorsCOVID-19 Drug TreatmentDrug RepositioningAntifungal AgentsCytokine Release SyndromeMycosesHumansMolecular Docking SimulationCOVID-19Molecular Dynamics SimulationSARS-CoV-2Cyclic Nucleotide Phosphodiesterases, Type 4

Stichwörter der Autor:innen

COVID‐19cytokine stormdrug repurposingphosphodiesterase‐4 inhibitorstriazole

Substanzen

TriazolesPhosphodiesterase 4 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 4Antifungal Agents

Autor:innen und Institutionen

  • Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Centre for Infectious Diseases & Microbiology, School of Public Health Sciences and Technology, Malla Reddy Vishwavidyapeeth, Hyderabad, Telangana, India.
  • Medicine Department, Prince Sultan Medical City (Psmmc), Riyadh, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Stem Cell Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Embryonic Stem Cell Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

ORCID-Profile: Bikram Dhara, Daniel Ejim Uti

Zitieren

APA

Almohaimeed, H. M., Chatterjee, A., Alaqabawi, M. R., Alsulaimani, F., Basri, A. M., Jafer, A., Shater, A. F., Saleh, F. M., Dhara, B., Uti, D. E., & Alum, E. U. (2025). Repositioning Triazoles as Phosphodiesterase‐4 Inhibitors to Suppress COVID ‐19 Cytokine Storms and Fungal Co‐Infections via Docking and Simulation. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70902

Vancouver

Almohaimeed HM, Chatterjee A, Alaqabawi MR, Alsulaimani F, Basri AM, Jafer A, et al. Repositioning Triazoles as Phosphodiesterase‐4 Inhibitors to Suppress COVID ‐19 Cytokine Storms and Fungal Co‐Infections via Docking and Simulation. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70902

BibTeX
@article{Almohaimeed2025,
  author = {Almohaimeed, Hailah M and Chatterjee, Aniruddha and Alaqabawi, Majedah Ramadan and Alsulaimani, Fayez and Basri, Ahmed M and Jafer, Ayman and Shater, Abdullah F and Saleh, Fayez M and Dhara, Bikram and Uti, Daniel Ejim and Alum, Esther Ugo},
  title = {Repositioning Triazoles as Phosphodiesterase‐4 Inhibitors to Suppress COVID ‐19 Cytokine Storms and Fungal Co‐Infections via Docking and Simulation},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70902}
}
Kostenlos starten →